Oxybutynin IVR - Juniper Pharmaceuticals

Drug Profile

Oxybutynin IVR - Juniper Pharmaceuticals

Alternative Names: JNP 0101; JNP-0101 intravaginal ring; Oxybutynin IVR

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juniper Pharmaceuticals
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Overactive bladder

Most Recent Events

  • 02 Nov 2017 Preclinical trials in Overactive bladder in USA (Vaginal)
  • 18 Sep 2017 Oxybutynin IVR - Juniper Pharmaceuticals is available for licensing as of 18 Sep 2017. http://www.juniperpharma.com/
  • 18 Sep 2017 Suspended - Preclinical for Overactive bladder in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top